Journals / Türk Geriatri Dergisi / 2017 / Cilt: 20 - Sayı: 1

ALZHEİMER HASTALIĞI VE VASKÜLER DEMANSTA EŞ ZAMANLI ALINAN SERUM VE BEYİN OMURİLİK SIVISINDA BİYOLOJİK BELİRTEÇLER

BIOMARKERS OF ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA SIMULTANEOUSLY SAMPLED FROM SERUM AND CEREBROSPINAL FLUID

Pages
1–7
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum interlukin-6 levels and cerebrospinal fluid ?-amyloid levels were significantly higher and lower, respectively, in Group 2 than in Group 1 (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Alzheimer's disease, which is a progressive disease accompanied by behavioral problems and decreased activities of daily living with early cognitive decline, and vascular dementia, which is related to cerebrovascular lesions with gradual, progressive cognitive decline, are common in the elderly.
📊
Key Findings & Data:In this study, cerebrospinal fluid and serum biomarker levels from both Alzheimer's disease and vascular dementia patients were examined.Materials and Method: Thirty patients diagnosed with Alzheimer's disease (Group 1) and vascular dementia (Group 2) were enrolled in this study.
💡
Conclusion & Impact:Serum interlukin-6 levels and cerebrospinal fluid ?-amyloid levels were significantly higher and lower, respectively, in Group 2 than in Group 1 (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Alzheimer's disease, which is a progressive disease accompanied by behavioral problems and decreased activities of daily living with early cognitive decline, and vascular dementia, which is related to cerebrovascular lesions with gradual, progressive cognitive decline, are common in the elderly. Currently, pathological examination is the gold standard in both Alzheimer's disease and vascular dementia and studies to elucidate the role of cytokines in their pathophysiology using cerebrospinal fluid and serum biological markers have been intensified. In this study, cerebrospinal fluid and serum biomarker levels from both Alzheimer's disease and vascular dementia patients were examined.Materials and Method: Thirty patients diagnosed with Alzheimer's disease (Group 1) and vascular dementia (Group 2) were enrolled in this study. Serum interleukin-1?, tumor necrosis factor--?, and interleukin-6 levels as well as serum and cerebrospinal fluid protein carbonyl, glutathione and ?-amyloid levels from Groups 1 and 2 (N=15 each) patients were compared.Results: Serum interleukin-1?, tumor necrosis factor-?, and ?-amyloid levels as well as serum and cerebrospinal fluid protein carbonyl and glutathione levels were not statistically different (p>0.05) between Group 1 and Group 2. Serum interlukin-6 levels and cerebrospinal fluid ?-amyloid levels were significantly higher and lower, respectively, in Group 2 than in Group 1 (p

Özet

Giriş: Kognitif bozulmanın ön planda olduğu, davranışsal sorunların ve günlük yaşamaktivitelerindeki bozulmanın eşlik ettiği, ilerleyici bir hastalık olan Alzheimer hastalığı veserebrovasküler faktörler ile ilişkili, basamaklı kognitif gerileme ile seyreden vasküler demanssıklıkla ileri yaş hastalığıdır. Günümüzde hem Alzheimer hastalığı hem de vasküler demans tanısındapatolojik inceleme altın standart olmakla birlikte, beyin omurilik sıvısı ve serumdaki biyolojikbelirteçler ile sitokinlerin patofizyolojideki rollerini ortaya çıkarmak için çalışmalar hız kazanmıştır.Bu çalışmada Alzheimer hastalığı ve vasküler demans hastalarının eş zamanlı alınan beyin omuriliksıvısı ve serumlarındaki biyolojik belirteç seviyeleri değerlendirilmiştir.Gereç ve Yöntem: Çalışmaya Alzheimer hastalığı (Grup 1) ve vasküler demans (Grup 2) tanısıkonulan 30 hasta alındı. Grup 1 (n=15) ve grup 2 (n=15) hastalarından eş zamanlı olarak serum vebeyin omurilik sıvısı alınarak serum interlökin-1?, tümör nekroz faktör-?, interlökin-6, serum vebeyin omurilik sıvısı protein karbonil, glutatyon, ?-amiloid düzeyleri ölçülüp karşılaştırıldı.Bulgular: Gruplar karşılaştırıldığında, serum interlökin-1?, tümör nekrozis faktör-?, ?-amiloid,serum ve beyin omurilik sıvısı protein karbonil, glutatyon düzeyleri istatistiksel olarak farklı değildi(p>0.05). Birinci gruba kıyasla ikinci grupta serum interlökin-6 düzeylerindeki yükseklik ile beyinomurilik sıvısı ?-amiloid düzeylerindeki düşüklük istatistiksel olarak anlamlıydı (p

🔖

Cite This Article

ÖZÖN, A. Ö., KARADAŞ, Ö., KONUKOĞLU, D., ÖZTÜRK, B., KOÇ, G. (2022). ALZHEİMER HASTALIĞI VE VASKÜLER DEMANSTA EŞ ZAMANLI ALINAN SERUM VE BEYİN OMURİLİK SIVISINDA BİYOLOJİK BELİRTEÇLER. Türk Geriatri Dergisi, Cilt: 20 - Sayı: 1, 1–7. https://ajindex.com/articles/623736

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Yaka E, Egrilmez MY, Keskinoğlu P, et al. Biochemical Markers in Cerebrospinal Fluid (CSF) and Evaluation of The Effect of CSF on PC12 Cell Line Viability in Alzheimer's Disease. Turkish Journal of Geriatrics 2006;9(1):1-7
  2. Kudiaki C. Prominent cognitive impairment in Alzheimer disease, vascular dementia and dementia with Lewy bodies. Turkish Journal of Geriatrics 2010;13:47-51
  3. Bingol A. Vascular Dementia, In: Emre M (Ed), Neurology Basic Book. 1st edition, Gunes, Ankara, Turkey 2013, pp 984-93. (in Turkish)
  4. Henley SM, Bates GP, Tabrizi SJ. Biomarkers for neurodegenerative diseases. Curr Opin Neurol 2005;18(6): 698-705. (PMID:16280682)
  5. Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K. Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull 2003;15;61(3):255-60. (PMID:12909295)
  6. De Luigi A, Fragiacomo C, Lucca U, Quadri P, Tettamanti M, Grazia De Simoni M. Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech Ageing Dev 2001;122(16):1985-95. (PMID:11589916)
  7. Konukoglu D, Fırtına S, Erkol G, Bolayırlı IM. Comparing Oxidative Stress Markers and S100B, A?-40 Proteins as Independent Neurological Markers in Distinguishing the Relation of Alzheimer's Disease and Diabetes Mellitus. J Neurol Neurosci 2016;7(5):146 (1-10)
  8. Zuliani G, Ranzini M, Guerra G, et al. Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. J Psychiatr Res 2007;41(8):686-93. (PMID:16600299)
  9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939-44. (PMID:6610841)
  10. Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43(2):250-60. (PMID:8094895)
  11. Angelopoulos P, Agouridaki H, Vaiopoulos H, et al. Cytokines in Alzheimer's disease and vascular dementia. Int J Neurosci 2008;118(12):1659-72. (PMID:18937113)
  12. Yasutake C, Kuroda K, Yanagawa T, Okamura T, Yoneda H. Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 2006;256(7):402-6. Erratum in: Eur Arch Psychiatry Clin Neurosci 2006;256(7):406. (PMID:16